273 related articles for article (PubMed ID: 19665938)
41. Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study.
Skljarevski V; Zhang S; Chappell AS; Walker DJ; Murray I; Backonja M
Pain Med; 2010 May; 11(5):648-57. PubMed ID: 20546509
[TBL] [Abstract][Full Text] [Related]
42. Brain functional changes and duloxetine treatment response in fibromyalgia: a pilot study.
Hunter AM; Leuchter AF; Cook IA; Abrams M; Siegman BE; Furst DE; Chappell AS
Pain Med; 2009; 10(4):730-8. PubMed ID: 19453962
[TBL] [Abstract][Full Text] [Related]
43. Worst, average or current pain in the Brief Pain Inventory: which should be used to calculate the response to palliative radiotherapy in patients with bone metastases?
Harris K; Li K; Flynn C; Chow E
Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):523-7. PubMed ID: 17566723
[TBL] [Abstract][Full Text] [Related]
44. The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials.
Beesdo K; Hartford J; Russell J; Spann M; Ball S; Wittchen HU
J Anxiety Disord; 2009 Dec; 23(8):1064-71. PubMed ID: 19643572
[TBL] [Abstract][Full Text] [Related]
45. Minimal clinically important change of the Neck Disability Index and the Numerical Rating Scale for patients with neck pain.
Pool JJ; Ostelo RW; Hoving JL; Bouter LM; de Vet HC
Spine (Phila Pa 1976); 2007 Dec; 32(26):3047-51. PubMed ID: 18091500
[TBL] [Abstract][Full Text] [Related]
46. Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials.
Mease PJ; Palmer RH; Wang Y
J Clin Rheumatol; 2014 Jun; 20(4):195-202. PubMed ID: 24847745
[TBL] [Abstract][Full Text] [Related]
47. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain.
Skljarevski V; Desaiah D; Zhang Q; Chappell AS; Detke MJ; Gross JL; Ziegler D
Diabetes Metab Res Rev; 2009 Oct; 25(7):623-31. PubMed ID: 19637208
[TBL] [Abstract][Full Text] [Related]
48. Minimally clinically significant differences for adolescents with chronic pain-variability of ROC-based cut points.
Hirschfeld G; Wager J; Schmidt P; Zernikow B
J Pain; 2014 Jan; 15(1):32-9. PubMed ID: 24268356
[TBL] [Abstract][Full Text] [Related]
49. Comparative responsiveness of verbal and numerical rating scales to measure pain intensity in patients with chronic pain.
Chien CW; Bagraith KS; Khan A; Deen M; Strong J
J Pain; 2013 Dec; 14(12):1653-62. PubMed ID: 24290445
[TBL] [Abstract][Full Text] [Related]
50. Brief pain inventory--facial minimum clinically important difference.
Sandhu SK; Halpern CH; Vakhshori V; Mirsaeedi-Farahani K; Farrar JT; Lee JY
J Neurosurg; 2015 Jan; 122(1):180-90. PubMed ID: 25361481
[TBL] [Abstract][Full Text] [Related]
51. Pain responder analysis: use of area under the curve to enhance interpretation of clinical trial results.
Cappelleri JC; Bushmakin AG; Zlateva G; Sadosky A
Pain Pract; 2009; 9(5):348-53. PubMed ID: 19549060
[TBL] [Abstract][Full Text] [Related]
52. Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials.
Irizarry MC; Webb DJ; Ali Z; Chizh BA; Gold M; Kinrade FJ; Meisner PD; Blum D; Silver MT; Weil JG
Clin J Pain; 2009; 25(6):469-76. PubMed ID: 19542793
[TBL] [Abstract][Full Text] [Related]
53. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale.
Salaffi F; Stancati A; Silvestri CA; Ciapetti A; Grassi W
Eur J Pain; 2004 Aug; 8(4):283-91. PubMed ID: 15207508
[TBL] [Abstract][Full Text] [Related]
54. Duloxetine in patients with diabetic peripheral neuropathic pain in Japan: a randomized, doubleblind, noninferiority comparative study with pregabalin.
Enomoto H; Yasuda H; Nishiyori A; Fujikoshi S; Furukawa M; Ishida M; Takahashi M; Tsuji T; Yoshikawa A; Alev L
J Pain Res; 2018; 11():1857-1868. PubMed ID: 30271191
[TBL] [Abstract][Full Text] [Related]
55. Minimum important differences for the patient-specific functional scale, 4 region-specific outcome measures, and the numeric pain rating scale.
Abbott JH; Schmitt J
J Orthop Sports Phys Ther; 2014 Aug; 44(8):560-4. PubMed ID: 24828475
[TBL] [Abstract][Full Text] [Related]
56. Clinical important improvement of chronic pain patients in randomized controlled trials and the DATAPAIN cohort.
Waardenburg S; de Meij N; Brouwer B; Van Zundert J; van Kuijk SMJ
Pain Pract; 2022 Mar; 22(3):349-358. PubMed ID: 34775674
[TBL] [Abstract][Full Text] [Related]
57. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis.
Pokrzywinski RM; Soliman AM; Snabes MC; Chen J; Taylor HS; Coyne KS
Fertil Steril; 2021 Feb; 115(2):423-430. PubMed ID: 33066973
[TBL] [Abstract][Full Text] [Related]
58. Clinical Relevance of Changes in Pain Intensity in Patients with Specific Back Pain.
Haase I; Kladny B
Z Orthop Unfall; 2022 Apr; 160(2):213-221. PubMed ID: 33461231
[TBL] [Abstract][Full Text] [Related]
59. Typology of patients with fibromyalgia: cluster analysis of duloxetine study patients.
Lipkovich IA; Choy EH; Van Wambeke P; Deberdt W; Sagman D
BMC Musculoskelet Disord; 2014 Dec; 15():450. PubMed ID: 25532971
[TBL] [Abstract][Full Text] [Related]
60. Minimally important change values of a measurement instrument depend more on baseline values than on the type of intervention.
de Vet HC; Foumani M; Scholten MA; Jacobs WC; Stiggelbout AM; Knol DL; Peul WC
J Clin Epidemiol; 2015 May; 68(5):518-24. PubMed ID: 25544741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
